Drug intelligence / Profile preview

TriCON

Development stage: Preclinical
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

TriCON (Triple Convergent Oncology Nanotherapy) is an experimental carbon-based, triple-modal nanotherapeutic platform designed for the treatment of pancreatic ductal adenocarcinoma (PDAC). The platform is engineered to address the highly malignant and immunosuppressive tumor microenvironment of pancreatic cancer through three synergistic mechanisms: CRISPR/Cas9-mediated gene editing of the poliovirus receptor (PVR/CD155), nano-encapsulated doxorubicin chemotherapy, and checkpoint blockade immunotherapy. TriCON is characterized by spatiotemporal convergence and stimuli-responsive controllability, allowing for precise release of its therapeutic payloads within the tumor. By knocking down PVR, the platform reverses tumor-induced immunosuppression and activates natural killer (NK) cells, while doxorubicin induces immunogenic cell death (ICD), collectively promoting robust antitumor activity and tumor regression in preclinical models.

Other names: Triple Convergent Oncology Nanotherapy

Targets

TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on TriCON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriCON.

Explore the full profile